MX2016008816A - Combinacion de un derivado de 6-oxo-1,6-dihidro-piridazina que tiene actividad anticancer con gefitinib. - Google Patents

Combinacion de un derivado de 6-oxo-1,6-dihidro-piridazina que tiene actividad anticancer con gefitinib.

Info

Publication number
MX2016008816A
MX2016008816A MX2016008816A MX2016008816A MX2016008816A MX 2016008816 A MX2016008816 A MX 2016008816A MX 2016008816 A MX2016008816 A MX 2016008816A MX 2016008816 A MX2016008816 A MX 2016008816A MX 2016008816 A MX2016008816 A MX 2016008816A
Authority
MX
Mexico
Prior art keywords
gefitinib
dihydro
oxo
combination
derivate
Prior art date
Application number
MX2016008816A
Other languages
English (en)
Inventor
Bladt Friedhelm
Friese-Hamim Manja
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX2016008816A publication Critical patent/MX2016008816A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Una composición farmacéutica de 3- (1-{3- [5- (1-metil-piperidin-4-ilmetoxi) -pirimidin-2-il] -bencil} -6-oxo-1,6-dihidro-piridazin-3-il)-benzonitrilo o una de sus sales y/o solvatos farmacéuticamente aceptables en combinación con Gefitinib.
MX2016008816A 2014-01-07 2014-12-16 Combinacion de un derivado de 6-oxo-1,6-dihidro-piridazina que tiene actividad anticancer con gefitinib. MX2016008816A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14000035 2014-01-07
PCT/EP2014/003366 WO2015104043A1 (en) 2014-01-07 2014-12-16 Combination of a 6-oxo- 1,6-dihydro-pyridazine derivate having anti-cancer activity with gefitinib

Publications (1)

Publication Number Publication Date
MX2016008816A true MX2016008816A (es) 2016-09-08

Family

ID=49916968

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016008816A MX2016008816A (es) 2014-01-07 2014-12-16 Combinacion de un derivado de 6-oxo-1,6-dihidro-piridazina que tiene actividad anticancer con gefitinib.

Country Status (16)

Country Link
US (1) US20160324855A1 (es)
EP (1) EP3091979A1 (es)
JP (1) JP2017502055A (es)
KR (1) KR20160106147A (es)
CN (1) CN105848658A (es)
AR (1) AR099036A1 (es)
AU (1) AU2014377080A1 (es)
CA (1) CA2935892C (es)
CL (1) CL2016001727A1 (es)
IL (1) IL246629A0 (es)
MX (1) MX2016008816A (es)
PH (1) PH12016500948A1 (es)
RU (1) RU2016132400A (es)
SG (1) SG11201605498VA (es)
TW (1) TW201609102A (es)
WO (1) WO2015104043A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3039401B1 (fr) * 2015-07-31 2018-07-13 Les Laboratoires Servier Nouvelle association entre le 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione et un inhibiteur de la tyr kinase du egfr
KR20200077193A (ko) 2018-12-20 2020-06-30 노수민 드론의 항공사진촬영을 활용한 농지법 위반 단속

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007032507A1 (de) * 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
BR112014022266A2 (pt) * 2012-03-19 2021-09-08 Merck Patent Gmbh Combinação de um derivado de 6-oxo-1,6-di-hidro-piridazina tendo atividade anticâncer com outros compostos antitumor
CN104245701A (zh) * 2012-04-03 2014-12-24 诺华有限公司 有酪氨酸激酶抑制剂的组合产品和其应用

Also Published As

Publication number Publication date
TW201609102A (zh) 2016-03-16
RU2016132400A3 (es) 2018-07-04
IL246629A0 (en) 2016-08-31
WO2015104043A1 (en) 2015-07-16
EP3091979A1 (en) 2016-11-16
CL2016001727A1 (es) 2016-12-16
KR20160106147A (ko) 2016-09-09
RU2016132400A (ru) 2018-02-13
CA2935892A1 (en) 2015-07-16
CA2935892C (en) 2022-08-02
JP2017502055A (ja) 2017-01-19
SG11201605498VA (en) 2016-08-30
AU2014377080A1 (en) 2016-08-18
CN105848658A (zh) 2016-08-10
US20160324855A1 (en) 2016-11-10
AR099036A1 (es) 2016-06-22
PH12016500948A1 (en) 2016-06-27

Similar Documents

Publication Publication Date Title
IL264186A (en) 2,5-dimutomers of 3-methylpyrazines and 2,5,6-dimutomers of 3-methylpyrazines as allosteric shp2 inhibitors
PH12016501809A1 (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
MY191574A (en) Pharmaceutical compositions comprising meloxicam
MX2016004340A (es) Compuestos heterociclicos y usos de los mismos.
DK2373640T3 (da) Hidtil ukendte polymorfe former af 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitril-hydrochloridsalt og fremgangsmåder til fremstilling deraf
MX2016012687A (es) Derivados de 2,4-tiazolidindiona en el tratamiento de trastornos del sistema nervioso central.
DK3395342T3 (da) Tablet omfattende 1-(3-(2-(1-benzothiophen-5-YL)ethoxy)propyl)azetidin-3-ol eller salt deraf
ZA201804387B (en) Pharmaceutical composition containing 2-{4-[n-(5,6- diphenylpyrazin-2-yl)-n-isopropylamino]butyloxy}-n- (methylsulfonyl)acetamide
PH12017500719A1 (en) Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with a quinazoline derivative
IL252744A0 (en) Solid forms comprising (1E,4E)-2-amino-N,N-dipropyl-8-(4-(pyrrolidine-1-carbonyl)phenyl)-3H-benzo[bi]azepine-4-carboxamide, their preparations and their uses
PH12017500718A1 (en) Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with an egfr inhibitor
AP3756A (en) Pharmaceutical administration forms comprising 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide
PH12016500948A1 (en) Combination of a 6-oxo- 1,6-dihydro-pyridazine derivate having anti-cancer activity with gefitinib
MX359110B (es) Combinacion de un derivado de 6-oxo-1,6-dihidro-piridazina que tiene actividad anticancer con un inhibidor de mek.
MX354518B (es) Derivado de 6-oxo-1, 6-dihidro-piridazina para uso en el tratamiento de carcinoma hepatocelular (hcc).
LT3408260T (lt) Kristalinė (2s,4r)-5-(5'-chlor-2-fluor-[1,1'-bifenil]-4-il)-2-(etoksimetil)-4-(3-hidroksi-izoksazol-5-karboksamido)-2-metilpentanoinė rūgštis ir jos panaudojimai
MX2017010304A (es) Composiciones farmaceuticas que comprenden meloxicam.
PH12016500964A1 (en) A 6-oxo-1,6-dihydro-pyridazine derivative for the use for the treatment of renal cell carcinoma (rcc)
MX2022000358A (es) Preparacion farmaceutica.
DK3585776T3 (da) 5-(pyrimidin-4-yl)-2-(pyrrolidin-1-yl)nicotinonitril-forbindelser som ikke, tbk1 og/eller sik2 kinaseinhibitorer
查尔斯 et al. PIANO ARTISTRY
UA88738U (uk) 5-(гептилтіо)-3-(феноксиметил)-1н-1,2,4-тріазол, що виявляє антигіпоксичну активність
UA98923U (ru) 3-((2-хлорэтил)тио)-4-этил-5(феноксиметил)-4н-1,2,4-триазола, проявляющей диуретическую активность
TH1501007248A (th) (+)-5-(3,4ไดฟลูออโรฟีนิล)-5-[(3-เมธิล-2-ออกโซไพริดิน-1(2h)-อิล)เมธิล] อิมิดาโซลิดีน-2,4-ไดโอน และ ยาที่ประกอบด้วยสิ่งเดียวกันนั้น
TH1601002081A (th) รูปแบบเภสัชภัณฑ์ซึ่งประกอบรวมด้วยโซเดียม 1-[6-(มอร์โฟลิน-4-อิล)ไพริมิดิน-4- อิล]-4-(1h-1,2,3-ไตรอะโซล-1-อิล)-1h-ไพราโซล-5-โอเลต